NeoProl Ltd.

Garti Nissim, HUJI, Faculty of Science, The Institute of Chemistry

Company Name


Year Company was Founded


Company Founders

Prof. Nissim Garti

About the Company

Established by Integra Holdings in 2014, NP-09 is at advanced preclinical development of an improved formulation of Propfol, based on technology developed by Prof. Nissim Garti from the Hebrew University. Current Propofol products are widely used for intravenous induction and maintenance of anesthesia, but are manufactured from animal and plant derived components with high risks of bacterial and fungal contamination leading to significant supply shortage, as well as significant manufacturer’s loss of revenues. NP09 is a novel bioequivalent Porpofol formulation with proven superiority over Diprivan.

Target Market/Potential

In 2015, Propofol products had a global market of over $1.2 Billion, expected to continue growing at a CAGR of over 7% per annum. Neoprol’s product, NP-09, with long duration patent exclusivity and improved pharmaceutical profile while maintaining bioequivalent effects, may have large market potential.

Company Website


Contact for more information:

Keren-Or Amar
VP, Business Development, Healthcare
Contact ME:
All projects by:Garti Nissim (3)